Ministry of Foreign Affairs of Japan Medical Visa Guarantee Agency No. B-66
Fukuoka Prefecture, Japan Travel service No. 35
Japanese Registration Support Organization No. 19-000303
Japan Medical Equipment Sales and Leasing
Medical Supporter
Accompanied with heart, medical care support in Japan
GcMAF Activated Macrophage Therapy
Saisemirai Medical Group
◎Regenerating the Future Klinic Activation Macrophage Therapy
(Macrophagy Activation Therapy GcMAF)
feature
1. Macrophages are cells that can engulf and digest cancer cells, viruses, and bacteria
like havingNK cellseffect.
Macrophages are amoeba-like cells differentiated from 5% of white blood cells in the blood, and they devour and digest invading bacteria, viruses, and foreign substances (such as cancer cells) in the body. There are two types of macrophages: M1 macrophages that activate immunity and M2 macrophages that suppress immunity.
However, recent studies have pointed out that in addition to the above two classification methods, there is another type of activation: classical activation, wound-healing macrophages, inhibitory or intermediate activation state.
2. After phagocytizing cancer cells, viruses, and bacteria, it can provide antigens to helper T cells and B lymphocytes
like havingDendritic cellseffect.
After macrophages acquire antigens, they release cytokines to activate specific T cells. Macrophages can decompose foreign matter into several fragments through phagocytosis, and combine the MHC-II possessed by the cells themselves, allowing the cells to be recognized. We also call this the cue antigen of macrophages.
3. According to the information provided by the hospital, it has been confirmed by animal experiments that GcMAF can inhibit the angiogenesis of cancer cells.
What is GcMAF?
1. A substance that can activate dormant immune cells (macrophages).
2. Gc protein is an activating factor, which is a key precursor substance of macrophages. If the Gc protein is cut off by the Nagalasesu enzyme secreted by cancer cells or HIV-infected lymphocytes, it will not be converted into a macrophage activating factor, which will cause macrophages to dormant and unable to act on cancer cells. Therefore, GcMAF is administered, and this GcMAF is a substance that can activate macrophages and promote macrophages to function, especially for cancer cells, AIDS, etc., and immune insufficiency.
3. Take out the Gc protein from about 240~360ml of patient's blood, treat it with enzymes in CPC (Cell Culture Center), produce GcMAF and inject it back into the body to turn on the immune switch, which is a therapy aimed at activating macrophages.
◎GcMAF activated macrophage therapy applicable objects
According to the data provided by regenerative future, GcMAF activated macrophage therapy is effective for cancer, AIDS, hepatitis B, hepatitis C, influenza, pneumonia, tuberculosis, EV virus infection and other diseases.
The side effects of this therapy are very small, and only reports of elevated body temperature and eczema have occurred in Europe. It can also be used in combination with other treatments, or with a small amount of steroids. Others, such as the combined use of chemotherapy target drugs, and immune combination therapy (thermotherapy, low-dose Naltrexone, lipoic acid, high-concentration vitamin C or Cloey vaccine) are all possible.
In addition, Dr. Akiyama recommends that patients take at least 5000IU of vitamin D health food every day. About 80% of cancer patients and AIDS patients have insufficient vitamin D in their blood. A normal supply of vitamin D is required for GcMAF to be fully active.
◎GcMAF activated macrophage therapy treatment introduction
The advantage of this treatment method is that the training period is short, and it only takes one week. There is also a corresponding method for patients whose condition is deteriorating and who are inconvenient to move. Different from other immune cell therapies, the completed GcMAF preparation is administered by intramuscular injection, just like the feeling of taking insulin. Dr. Akiyama mentioned that depending on the condition of the patient, the dosage may be twice a day Or more. In principle, intramuscular injections are given 3 to 7 times a week, and the frequency and method of injections are determined after consultation.
Mechanism:
a. Phagosomes engulf foreign bodies.
b. Phagosomes are formed by the fusion of lysosomes and phagolysosomes,
Foreign matter is destroyed by enzymatic digestion.
c. The residue is excreted by the cell (or digested)
1. Foreign body (pathogen) 2. Phagosome 3. Lysosome 4. Residue 5. Cytoplasm
6. Cell membrane
◎GcMAF activated macrophage therapy literature
◎November 13, 2016, at the BREEZE PLAZA in Osaka, an international large-scale advanced medical conference hosted by the medical corporation Regenerate Future. Many cancer specialists from home and abroad came to this venue to give lectures on cutting-edge treatment methods and treatment cases.
→Summary of the Advanced Medical International Conference Osaka 2016
◎September 24, 2016, Dr. Gan Lifu, chairman of the medical corporation Regeneration Future, announced at the Four Seasons Hotel Sydney, Australia.
→Genostics Conference official website
◎July 14-15, 2016, Dr. Akiyama delivered a keynote speech on Clinical experience of colostrum derived protein against solid cancer at the International Pharmacy Conference held in Philadelphia, Pennsylvania, USA.
→ Dr. Akiyama published content
◎On December 7, 2013, the 17th academic meeting of the Japan Biochemical Therapy Research Association was held at Fukuoka University, and Associate Professor Uto and Dean Gan of Tokushima University, who conducted joint research with Regeneration Future, made a presentation. The title of Dean Gan’s presentation is: Case Report: A Breast Cancer Patient Treated with GcMAF Sonodynamic Treaty and Hormone Therapy. Dean Gan’s slideshow is written in English, and interested friends can download it by clicking the chart next to it. Case presentations and data on breast cancer patients in combination with other therapies.
Professor Utsushi published materials
Information published by Dean Qian (English)
◎Other relevant literature on GcMAF can also be downloaded from the link next to it, and the English version is provided for your reference:
◎About Regenerative Future
Regeneration Future Clinic has four bases in Japan, which are divided into branches according to different attributes, such as dermatology and cancer treatment. They are in Tokyo, Osaka, and Kobe respectively. There are a total of six clinics in operation, which can be regarded as medical institutions with a wide distribution. In addition, in terms of academic research, Reborn Future has conducted joint research with Tokushima University, the Affiliated Hospital of Kobe University Faculty of Medicine, Kyoto Prefectural University of Medicine, and Konan University. Like general immunotherapy institutions, they provide T+NK treatment, and the most special thing is that there is a kind of "activated macrophage therapy". As we introduced above, medical institutions that use allogeneic immunity in Japan are really rare. There are many, and there is also an additional treatment method for patients who are unable to go to Japan for medical treatment due to illness.
There are other treatment methods in regenerative medicine, such as gene therapy, ultrasound, etc. Medical assistants will translate the gene therapy information provided by regenerative future for your reference.
◎Regenerative Future Introduction to Gene Therapy
The introduction webpage of gene therapy for regenerative medicine is:http://www.saisei-mirai.or.jp/gan/gene_remedy.html
◎New gene therapy JG-1
Novel gene therapy JG-1 is two powerful cancer gene therapy of CDC6 shRNA active gene and cancer suppressor gene p16.
The CDC6 shRNA active gene is one of the characteristics of cancer. It eliminates CDC6, the initial replication factor found in many cancer cells, and inhibits the infinite proliferation mechanism. p16 is the repair suppressor oncogene Rb, which acts as the starting point for the arrest of cell cycle initiation of cell proliferation. Coupled with the stimulation of p53, known as the patron saint of genes, it effectively promotes the self-destruction of cancer cells. The most efficient gene therapy lentivirus vector (Lentivirus vector) is used for gene loading.
◎Characteristics of Cancer Gene Therapy
-
Few resistant treatments.
-
It requires a two-and-a-half-hour drip, or localized injection, so no hospitalization is required.
-
Because it does not cause damage to normal cells, it is a treatment with very few side effects.
-
Optimal dynamic ultrasound therapy, immunotherapy, hyperthermia, chemotherapy, and radiation therapy are effective in combination, and high-concentration vitamin C or low-dose Naltrexone can also be used in combination.
-
It is applicable to a wide range of cancers, and there is no age limit. It is applicable to most cancers.
◎Regenerative Future Physician Group Introduction
According to the information on the website, there are six physicians in Reborn Future, namely Shinichiro Akiyama, Sawako Hibino, Masamitsu Ichihashi, Tomohiko Yamamoto, Toshio Miri, and Hitoshi Hida. The following introduces the resumes of the chief dean and the chairman of the board for your reference. Content excerpted from:Reborn Future's official websitePhysician introduction
Shinichiro Akiyama
SHIICHIRO AKIYAMA
chairman dry leaf
TOSHIO INUI
We Are
MOVERS & SHAKERS
Introduction
Graduated from Sapporo Medical University, currently serving as the dean of Tokyo R Future がん International Clinic, previously worked as the medical director of the Space Medicine Research and Development Office of the Space Development Corporation, the deputy director of Suido Sakura Hospital, the chief dean of Kudan Clinic and the director of CPC, Director of UDX Hirahata Klinic.
Experience - Affiliated Society
Lecturer at McGill University
World Association of Physicians
American Academy of Internal Medicine
American Society of Clinical Oncology
American Cancer Society
American Chemical Society
American Association for the Advancement of Science
Life Member of International Society for Dendritic Cell & Vaccine Science
Introduction
After graduating from Kyoto Prefectural University of Medicine in 1978 and working in a general hospital, he started his own business at the age of 33. Due to the friendly and meticulous diagnosis and treatment, about 400 patients visit the doctor a day, and they are still seeing the doctor until late at night. In 2010, he founded the Living Future Clinic in Kobe, and now cooperates with overseas medical institutions to continue the research and development of new immunotherapy.
Since the Regenerative Future Medical Group has two areas of skin and cancer treatment, the contact information and addresses of the following three branches specializing in cancer treatment are as follows.
Osaka: Dry Gan Immunity Clinic
〒570-0011 6-14-17 Kaneda-cho, Moriguchi City, Osaka Prefecture
Kobe: Renewing the Future Clinic Kobe
〒651-0083 23F, Kobe Shoko Trading Center, 5-1-14 Hamabedori, Chuo-ku, Kobe City, Hyogo Prefecture
Tokyo: R Future がん International Club
〒106-0047 5-10-26 ORE Hiroo Building 7F, Minami Azabu, Minato-ku, Tokyo
◎Clinic address
If you have any questions, please feel free to contact us through any of the methods below.
CONTACT US
TW contact only: ＋886-90-5563-717
JP For emergency contact: ＋81-80-4276-3930
JP Tel / Fax: ＋81-92 -984-3200
Mail: service@medicalsupporter.org
LINE@ ID: @medicalsupporter
LINE & WeChat & Skype: medicalsupporter
LINE@
LINE
